#United States #Washington, D.C. #Evolent Health #Performance Suite #Oncology Care Partners

Evolent Health's Third Quarter 2025 Results

Evolent Health, Inc. (NYSE: EVH), dedicated to enhancing health outcomes for individuals facing complex conditions, has unveiled its financial results for the third quarter of 2025. This report highlights significant progress and promising developments for the upcoming year.

Financial Performance Overview

In the three months concluding on September 30, 2025, Evolent reported revenues amounting to $479.5 million, a notable decrease from $621.4 million during the same period in 2024. Despite this drop, the company achieved an Adjusted EBITDA of $38.96 million, up from $31.80 million the previous year, signifying resilience in operations despite challenging market conditions.

Key Financial Metrics:

• - Net Loss: $26.93 million (compared to a net loss of $31.23 million in Q3 2024)
• - Adjusted EBITDA Margin: 8.1%, an improvement from 5.1% a year ago
• - Total Revenue Expected for 2025: Approximately $1.87 to $1.88 billion

CEO Seth Blackley expressed optimism regarding these results, stating, "We are pleased to demonstrate strong quarterly performance, achieving results in the upper range of our guidance for adjusted earnings growth and total revenue, while reaffirming our outlook for Q4."

Continued Growth and Strategic Partnerships

The company has secured two new customer agreements, bringing its contract total for the year to 13. Evolent expects to generate over $750 million in new annualized revenue in 2026 through these agreements, strengthening its position in the healthcare market. One new contract will see Evolent's Performance Suite used across 650,000 members in oncology, reflecting growing demand for comprehensive health solutions.

Blackley added, "With our proven Enhanced Performance Suite model, we are committed to smart growth while maintaining margin discipline, and our innovations in member navigation and Oncology Care reflect this commitment."

Leadership Expansion

To bolster its growth trajectory, Evolent announced significant leadership changes. Mario Ramos, previously CFO of CVS Caremark, will step into the CFO role on January 1, 2026. He brings vast experience to the company, having overseen complex acquisitions and risk-based care operations.

Blackley commented, "We see Mario's arrival as a pivotal move for our future, especially in the oncology sector, where his expertise will be invaluable."

Additionally, Emily Rafferty will transition from Chief Operating Officer to Executive Vice President, Customer Success, while Katie DiPerna will take on the COO role with the mandate to enhance customer operations amidst rapid growth.

Looking Ahead: 2025 Guidance

Evolent anticipates Q4 2025 revenue between $462 million to $472 million and forecasts for an overall Adjusted EBITDA between $30 million to $40 million. The company expects to allocate roughly $35 million toward capitalized software development in 2025 as part of its broader growth strategy.

Conclusion

Evolent Health continues to navigate the complexities of the healthcare landscape effectively, delivering results that reflect its commitment to improving health outcomes while maintaining financial discipline. Looking forward, the strategic partnerships and leadership expansions indicate a strong foundation for future growth as the company adapts to meet the evolving needs of its clientele.

For more information on Evolent Health’s financial performance and future outlook, visit their Investor Relations page.